Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo…
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are…
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease1 New results show…
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer…
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024…
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the…
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at…
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced…
Toronto, Ontario--(Newsfile Corp. - September 13, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K9) ("Quantum BioPharma" or…